Previous 10 | Next 10 |
Cellular Biomedicine (NASDAQ: CBMG ): Q2 GAAP EPS of -$0.63 misses by $0.11 . More news on: Cellular Biomedicine Group, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
NEW YORK and SHANGHAI , Aug. 6, 2019 /PRNewswire/ -- Cellular Biomedicine Group Inc. (NASDAQ: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today repo...
NEW YORK and SHANGHAI , July 23, 2019 /PRNewswire/ -- Cellular Biomedicine Group Inc. (NASDAQ: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today announced ...
The following healthcare companies have filed prospectuses for mixed shelf offerings: More news on: Translate Bio, Inc., Cellular Biomedicine Group, Inc., Iterum Therapeutics plc, Healthcare stocks news, Read more ...
Deals and Financings Beijing's BeiGene ([[BGNE]]; HK: 06160) will receive a $150 million termination payment from Celgene (CELG) because Celgene will end its $1.4 billion partnership for ex-China rights to BeiGene's PD-1 candidate. The original deal included a provision that BeiGene's ti...
NEW YORK and SHANGHAI , June 18, 2019 /PRNewswire/ -- Cellular Biomedicine Group Inc . (NASDAQ: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today ann...
NEW YORK and SHANGHAI , June 17, 2019 /PRNewswire/ -- Cellular Biomedicine Group Inc. (NASDAQ: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today ann...
NEW YORK and SHANGHAI , May 29, 2019 /PRNewswire/ -- Cellular Biomedicine Group, Inc . (Nasdaq: CBMG) (CBMG or the Company), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today announced th...
NEW YORK and SHANGHAI , May 20, 2019 /PRNewswire/ -- Cellular Biomedicine Group, Inc . (Nasdaq: CBMG) (CBMG or the Company), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today announc...
Cellular Biomedicine Group, Inc. (CBMG) Q1 2019 Earnings Conference Call May 1, 2019 08:30 AM ET Company Participants Tony Liu - Executive Director, CEO, CFO Derrick Li - Head of Strategy & IR Conference Call Participants Madhu Kumar - Robert W. Baird George Zavoico - B...
News, Short Squeeze, Breakout and More Instantly...
Cellular Biomedicine Group Inc. Company Name:
CBMG Stock Symbol:
NASDAQ Market:
Cellular Biomedicine Group Inc. Website:
Cellular Biomedicine Group, Inc. Announces Completion of Merger PR Newswire ROCKVILLE, Md. and SHANGHAI , Feb. 19, 2021 /PRNewswire/ -- Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) ("CBMG" or the "Company") today announced the completion of the merger (th...
Cellular Biomedicine Group, Inc. Stockholders Approve Merger PR Newswire ROCKVILLE, Md. and SHANGHAI , Feb. 8, 2021 /PRNewswire/ -- Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) ("CBMG" or the "Company") announced that, at the Company's special meeting...
Leading Proxy Advisory Firms Glass Lewis and ISS Recommend Cellular Biomedicine Group Stockholders Vote FOR Proposed Merger PR Newswire ROCKVILLE, Md. and SHANGHAI , Jan. 28, 2021 /PRNewswire/ -- Cellular Biomedicine Group, Inc. (Nasdaq: CBMG) ("Company,...